beta
Trial Radar AI
One study matched filter criteria
Card View
Back to Search

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity Phase 4 40

Recruiting
Clinical Trial NCT07218445 is designed to study Treatment for Obesity, Menopause Hot Flashes. It is a Phase 4 interventional study that is recruiting, having started on April 1, 2026, with plans to enroll 40 participants. Led by Mayo Clinic, it is expected to complete by September 18, 2027. The latest data from ClinicalTrials.gov was last updated on March 24, 2026.
Brief Summary
The purpose of this study is to determine the effect of tirzepatide on vasomotor symptoms and on measures of biological aging.
Official Title

The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity: A Pilot Study

Conditions
ObesityMenopause Hot Flashes
Other Study IDs
  • 25-001692
NCT ID Number
NCT07218445
Start Date (Actual)
2026-04
Last Update Posted
2026-03-24
Completion Date (Estimated)
2027-09-18
Enrollment (Estimated)
40
Study Type
Interventional
PHASE
Phase 4
Status
Recruiting
Keywords
Hot flashes
menopause
Tirzepatide
GLP
Primary Purpose
Treatment
Design Allocation
Randomized
Interventional Model
Parallel
Masking
Quadruple
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalTirzepatide
Participants will receive tirzepatide for 24 weeks, in addition to standard lifestyle modification recommendations
Tirzepatide
Tirzepatide will be administered with a starting dose of 2.5 mg weekly, subcutaneously injected. The dose will increase by 2.5 mg every 4 weeks until reaching 15 mg. Participants will be asked to follow lifestyle interventions: * Low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day * Physical activity: a goal of 10,000 steps or more per day * Exercise: a goa...Show More
Placebo ComparatorPlacebo
Participants will receive a placebo for 24 weeks, in addition to standard lifestyle modification recommendations
Placebo
A placebo for Tirzepatide will be administered with a starting dose of 2.5 mg weekly, subcutaneously injected. The dose will increase by 2.5 mg every 4 weeks until reaching 15 mg. Participants will be asked to follow lifestyle interventions: * Low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day * Physical activity: a goal of 10,000 steps or more per day * E...Show More
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in Vasomotor Symptoms Frequency
Change in the frequency of self-reported daily average vasomotor symptoms from baseline to 24 weeks. Vasomotor symptoms will be captured for 2 weeks at baseline and 2 weeks at the end of the study.
Baseline, 24 weeks
Change in Vasomotor Symptom Severity
Change in self-reported daily vasomotor symptom severity from baseline to 24 weeks. Vasomotor symptoms will be captured for 2 weeks at baseline and at the end of the study. Severity will be classified as follows: Mild, sensation of heat without sweating/dampness; Moderate: sensation of heat with sweating/dampness, but able to continue current activity. May briefly fan yourself; Severe: sensation of intense heat with sweating causing disruption of current activity.
Baseline, 24 weeks
Aging Biomarkers: Cellular Senescence Markers in Plasma
Cellular senescence markers are measured in plasma samples to assess biological aging and cellular stress. These markers may include proteins associated with the senescence-associated secretory phenotype (SASP). Quantification is performed using immunoassays. Higher levels of senescence markers indicate increased cellular senescence.
24 weeks
Difference between biological and chronological age
Epigenetic clocks estimate biological age by analyzing DNA methylation patterns at specific CpG sites across the genome. Biological age estimates are compared to chronological age to assess aging acceleration or deceleration. Biological age greater than chronological age indicates accelerated biological aging and potential increased risk of morbidity and mortality. Primary measure is the difference (ΔAge) between biological and chronological ages = reported in years.
24 weeks
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in Reactive hyperemic index
Vascular function will be measured using the EndoPAT device to assesses reactive hyperemia index (RHI) from baseline to week 24 on treatment or placebo. RHI is automatically calculated through a computer algorithm by following the equation: \[(tested arm-post occlusion/tested arm-baseline)/(control arm-post occlusion/control arm-baseline)\] × baseline correction factor. Endothelial dysfunction is defined as having an RHI ratio of equal or less than 1.67.
Baseline, 12 weeks and 24 weeks
Change in Augmentation Index percentage
Augmentation Index (AIx): AIX uses applanation tonometry of the radial artery pulse, calibrated to resting brachial systolic and diastolic pressures (SphygmoCor XCEL, Medtronic, Minneapolis, MN). Aortic systolic, diastolic, and pulse pressures will be derived from a synthesized aortic waveform using a validated mathematical transfer function. Augmentation pressure, reflecting the difference between aortic systolic pressure and the inflection point caused by the reflected wave, is influenced by arterial stiffness as well as factors like heart rate and ejection dynamics. AIx is calculated as augmentation pressure divided by aortic pulse pressure × 100%, adjusted to a heart rate of 75 bpm (AIx@75 bpm). Measurements will be performed in duplicate and averaged.
Baseline, 12 weeks, and 24 weeks
Change in Pulse Wave Velocity
SphygmoCor estimates central arterial stiffness by calculating the speed at which the pressure wave travels between the carotid and femoral arteries using applanation tonometry and reported as the pulse wave velocity (PWV); PWV m/s
Baseline, 12 weeks, and 24 weeks
Change in Cardiometabolic Parameters: Blood Pressure
Change in cardiometabolic parameters including blood pressure from baseline to week 24 on treatment or placebo. Measured in mmhg
Baseline, 24 weeks
Change in Cardiometabolic Parameters: Fasting Glucose
Change in cardiometabolic parameters including fasting glucose from baseline to week 24 on treatment or placebo. Measured in mg/dL
Baseline, 24 weeks
Changes in Cardiometabolic Parameters: HbA1C
Change in cardiometabolic parameters including HbA1C from baseline to week 24 on treatment or placebo. Measured in %
Baseline, 24 weeks
Changes in Cardiometabolic Parameters: Lipoprotein profile
Change in cardiometabolic parameters including Lipoprotein profile from baseline to week 24 on treatment or placebo. Measured in mg/dL
Baseline, 24 weeks
Changes in Cardiometabolic Parameters: hsCRP
Change in cardiometabolic parameters including hsCRP from baseline to week 24 on treatment or placebo. Measured in mg/L
Baseline, 24 weeks
Change in Physical Function Measure: Short Physical Performance Battery (SPPB) score.
The SPPB is a standardized test that evaluates lower extremity function using three components: balance tests (standing in various positions), gait speed (walking a short distance), and chair stand (repeated standing from a seated position). Each component is scored from 0 to 4; the total score ranges from 0 to 12. Higher scores represent better physical function
Baseline, 24 weeks
Change in Physical Function Measure: Modified Clinical Test of Sensory Interaction in Balance (mCTSIB) performed on the Rehabilitation Artificial Physical Intelligence Database (RAPID) foot pressure mat
The mCTSIB assesses balance under four sensory conditions: eyes open/closed on firm and foam surfaces. Testing is performed while standing on the RAPID foot pressure mat, which captures center of pressure and postural sway data. The primary measure is average sway area of the four sensory conditions. The sway area is the area which is required to correct equilibrium, representing the total area covered by postural sway, measured in square centimeters (cm²).
Baseline, 24 weeks
Change in Physical Function Measure: Standing Chest Throw Test with a 2-kg Weighted Ball using Motion Sensor Technology (MST)
This test evaluates upper body muscular power. Participants perform a two-handed chest throw of a 2-kg medicine ball from a standing position. The MST is used to record throw distance, velocity, and related performance metrics. The primary measure is Peak Power Score (W).
Baseline, 24 weeks
Change in Physical Function Measure: Chair-to-Stand Tests using Motion Sensor Technology (MST)
This test assesses lower body strength and function. Participants are instructed to stand up from a chair and sit back down five times without using their arms. The MST measures movement dynamics. The primary measure is peak power score (W).
Baseline, 24 weeks
Change in Physical Function Measure: Six-Minute Walk Test (6MWT)
The 6MWT is a standardized submaximal exercise test used to assess functional aerobic capacity. Participants are instructed to walk as far as possible in six minutes along a flat, straight course. The total distance walked is recorded in feet. Longer walking distances indicate better aerobic capacity and endurance.
Baseline, 24 weeks
Change in Physical Function Measure: Hand Grip Strength using a Hydraulic Hand Dynamometer
Participants are instructed to squeeze the dynamometer with maximum effort, measured in kilograms. The highest value from multiple trials is recorded.
Baseline, 24 weeks
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
46 Years
Eligible Sexes
Female
Accepts Healthy Volunteers
Yes
  • Postmenopausal women defined as 12 months of spontaneous amenorrhea, or 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone (FSH) levels > 40 mIU/ml, or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
  • Age 46-60 years old.
  • BMI ≥30 kg/m2 or BMI ≥27 kg/m2 in the presence of adiposity-associated diseases (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease).
  • Presence of bothersome hot flashes (≥ 28 episodes per week and of sufficient severity to prompt patients to seek therapeutic interventions).
  • Hot flashes must be present for >30 days prior to study entry.
  • Ability to participate in all portions of the study, including willingness to self-inject drug
  • Provided informed consent to be part of the study.
  • Willingness and capability to follow a hypocaloric diet, consisting of an energy deficit of approximately 500 kcal/day compared to baseline total energy expenditure, and composed of 30% from fat, 20% from protein, and 50% of carbohydrate. In addition to performing at least 150 min/week of physical activity

  • Current treatment with menopausal hormone therapy.

  • Any current (past 4 weeks) or planned use of:

    • Estrogen-containing contraceptive methods or menopausal hormone therapy (oral, transdermal, high dose vaginal ring, injection, pellets).
    • Vaginal estrogen.
    • Androgens.
    • Progestogens.

  • Current treatment for menopausal symptoms with cognitive behavioral therapy and/or hypnosis.

  • Current use of fezolinetant.

  • Menopause as a result of cancer treatments.

  • Impaired renal function (GFR ≤30 ml/min/1.73 m²).

  • Thyroid-stimulating hormone ≥7 with low free T4.

  • 10-year ASCVD risk > 7.5%.

  • Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignancy, or uncontrolled psychiatric disease.

  • >5% change in weight during the 3 months prior to screening and, or eight fluctuation of ≥20 pounds within the past 6 months (self-report).

  • Other obesity medication used within the past 3 months.

  • History of bariatric surgery. Prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty performed > 1 year before screening).

  • Past or intended endoscopic and/or device-based therapy or removal within last six months.

  • Current or recent (within 3 months) use of medications that may cause weight gain, including tricyclic antidepressants, atypical antipsychotics, and mood stabilizers.

  • Current or recent (within 3 months) use of chronic systemic glucocorticoid therapy for over 2 weeks within the past 3 months.

  • Contraindications to GLP-1 receptor agonist therapy as per Tirzepatide (Zepbound ®) label, including a personal or family history of medullary thyroid carcinoma; a history or diagnosis of multiple endocrine neoplasia syndrome type 2; known hypersensitivity to tirzepatide or any of its excipients.

  • Currently enrolled in another clinical study involving an investigational product, or participated in one and received treatment (active or placebo) in the last 30 days.

  • Planned surgical procedures requiring general anesthesia or sedation during the study or within 2 weeks following the last dose of study drug.

Mayo Clinic logoMayo Clinic861 active studies to explore
Study Responsible Party
Chrisandra L. Shufelt, MD, Principal Investigator, Principal Investigator, Mayo Clinic
Study Central Contact
Contact: Aubri Robbins, BHSc, 904-953-4712, [email protected]
Contact: Alysha Stephens, 904-953-7846, [email protected]
1 Study Locations in 1 Countries

Florida

Mayo Clinic in Florida, Jacksonville, Florida, 32224, United States
Aubri Robbins, BHSc, Contact, 904-953-4712, [email protected]
Chrisandra Shufelt, MD, Principal Investigator
Recruiting